Lupus Atherosclerosis Prevention Study (LAPS)

Michelle A. Petri, A. N. Kiani, W. Post, L. Christopher-Stine, L. S. Magder

Research output: Contribution to journalArticlepeer-review

Abstract

Background: Cardiovascular disease is one of the major causes of death in systemic lupus erythematosus (SLE). A study was undertaken to investigate whether treatment with statins would reduce subclinical measures of atherosclerosis over a 2-year period. Methods: 200 patients with SLE without clinical cardiovascular disease were randomised to receive atorvastatin 40 mg daily or an identical placebo. At baseline and after 2 years of follow-up, helical CT scanning (for coronary artery calcium) and carotid duplex (for intima media thickness/plaque) were performed. Patients were seen for measures of disease activity at 1 month, 3 months and quarterly thereafter. The primary outcome variable was change in coronary artery calcium. Results: At baseline, 43% had coronary artery calcium. At 2 years there was no significant difference between the groups in progression of coronary artery calcium, carotid intima media thickness or carotid plaque. There was no significant difference between the groups in disease activity, measures of inflammation or endothelial cell activation. Conclusion: This study provides no evidence that atorvastatin reduces subclinical measures of atherosclerosis or disease activity over 2 years in patients with SLE. In fact, it does not appear to reduce biochemical measures of inflammation. The antiinflammatory effects of statins observed in the general population were not replicated in this SLE clinical trial. Clinical trials.gov (NCT 00120887).

Original languageEnglish (US)
Pages (from-to)760-765
Number of pages6
JournalAnnals of the rheumatic diseases
Volume70
Issue number5
DOIs
StatePublished - May 2011

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint

Dive into the research topics of 'Lupus Atherosclerosis Prevention Study (LAPS)'. Together they form a unique fingerprint.

Cite this